RT Journal Article
SR Electronic
T1 Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.23.23290344
DO 10.1101/2023.05.23.23290344
A1 Brumm, Michael C.
A1 Siderowf, Andrew
A1 Simuni, Tanya
A1 Burghardt, Elliot
A1 Choi, Seung Ho
A1 Caspell-Garcia, Chelsea
A1 Chahine, Lana M.
A1 Mollenhauer, Brit
A1 Foroud, Tatiana
A1 Galasko, Douglas
A1 Merchant, Kalpana
A1 Arnedo, Vanessa
A1 Hutten, Samantha J.
A1 O’Grady, Alyssa N.
A1 Poston, Kathleen L.
A1 Tanner, Caroline M.
A1 Weintraub, Daniel
A1 Kieburtz, Karl
A1 Marek, Kenneth
A1 Coffey, Christopher S.
A1 
YR 2023
UL http://medrxiv.org/content/early/2023/05/24/2023.05.23.23290344.abstract
AB Background Identifying a meaningful progression metric for Parkinson’s disease (PD) that reflects heterogeneity remains a challenge.Objective To assess the frequency and baseline predictors of progression to clinically relevant motor and non-motor PD milestones.Methods Using data from the Parkinson’s Progression Markers Initiative (PPMI) de novo PD cohort, we monitored 25 milestones across six domains (“walking and balance”; “motor complications”; “cognition”; “autonomic dysfunction”; “functional dependence”; “activities of daily living”). Milestones were intended to be severe enough to reflect meaningful disability. We assessed the proportion of participants reaching any milestone; evaluated which occurred most frequently; and conducted a time-to-first-event analysis exploring whether baseline characteristics were associated with progression.Results Half of participants reached at least one milestone within five years. Milestones within the cognitive, functional dependence, and autonomic dysfunction domains were reached most often. Among participants who reached a milestone at an annual follow-up visit and remained active in the study, 82% continued to meet criteria for any milestone at one or more subsequent annual visits and 55% did so at the next annual visit. In multivariable analysis, baseline features predicting faster time to reaching a milestone included age (p<0.0001), greater MDS-UPDRS total scores (p<0.0001), higher GDS-15 depression scores (p=0.0341), lower dopamine transporter binding (p=0.0043), and lower CSF total α-synuclein levels (p=0.0033). Symptomatic treatment was not significantly associated with reaching a milestone (p=0.1639).Conclusions Clinically relevant milestones occur frequently, even in early PD. Milestones were significantly associated with baseline clinical and biological markers, but not with symptomatic treatment. Further studies are necessary to validate these results, further assess the stability of milestones, and explore translating them into an outcome measure suitable for observational and therapeutic studies.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.ppmi-info.org/study-design Funding StatementPPMI - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research funding partners 4D Pharma, Abbvie, Acurex Therapeutics, Aligning Science Across Parkinson's, Allergan, Amathus Therapeutics, Avid Radiopharmaceuticals, Bial Biotech, Biogen, BioLegend, Bristol-Myers Squibb, Calico, Celgene, Dacapo Brain Science, Denali, The Edmond J. Safra Foundaiton, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lilly, Lundbeck, Merck, Meso Scale Discovery, Neurocrine Biosciences, Pfizer, Piramal, Prevail, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, and Voyager Therapeutics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data (downloaded from https://www.ppmi-info.org/access-data-specimens/download-data) were openly available before the initiation of the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://www.ppmi-info.org/access-data-specimens/download-data. https://www.ppmi-info.org/access-data-specimens/download-data